TB-500 / Thymosin Beta-4

TB-500 is based on a fragment of Thymosin Beta-4, a protein that helps cells move and change shape. That movement is central to how tissues repair.

It's studied in wound healing and recovery research. Researchers look at how skin closes, how cells migrate, and how muscle and skin rebuild.

Animal studies showed faster skin healing with less scarring. Human evidence is limited and not established.

Distinguishes established clinical findings from early human trials, animal experiments, or laboratory cell culture findings. No human dosing, injection instructions, or treatment recommendations are provided.

TB-500 / Thymosin Beta-4 is investigational. It is not FDA-approved for human medical use.

BBOHC LABS research reagents are non-clinical materials. An FDA approval for a finished medicine containing the same active ingredient does not imply that BBOHC's investigational research vial is FDA-approved.

Encourages new small blood vessels; exclude from tumor-tissue experiments.

• Goldstein AL et al. Thymosin beta4: actin-sequestering protein and candidate drug. Expert Opin Biol Ther. 2012.

Specific citations are provided for literature context. Product purity & lot verification documentation available on request.